Drug Trial Radar · NCT00924703
Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
Last checked: Nov 20, 2026Latest source record: Oct 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jan 13, 2010
Primary completion
Jan 31, 2019
Study completion Jan 31, 2019
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jun 19, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
Conditions
- Phenylketonuria
Interventions
rAvPAL-PEGDrug
The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Blood Phenylalanine (Phe) ConcentrationTime frame: At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
The Children's Hospital
Aurora, Colorado
University of Florida
Gainesville, Florida
Ann and Robert H Lurie Children's Hospital
Chicago, Illinois
University of Louisville, Kosair Charities Pediatric Clinical Research Unit
Louisville, Kentucky
Children's Hospital Boston
Boston, Massachusetts
University of Missouri
Columbia, Missouri
Washington University Center for Applied Research Sciences
St Louis, Missouri
Nebraska Medical Center
Omaha, Nebraska
Albany Medical Center
Albany, New York
Mount Sinai School of Medicine
New York, New York
Oregon Health and Science University
Portland, Oregon
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
University of Utah Hospital
Salt Lake City, Utah
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.